

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

DATE MAILED: 11/21/2003

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/901,214	07/09/2001	Gordon L. Amidon	PSL-10202/39	6240
75	90 11/21/2003		EXAM	INER
Gifford, Krass, Groh, Sprinkle,			HUI, SAN MING R	
Anderson & Cit	kowski, P.C.			
Suite 400			ART UNIT	PAPER NUMBER
280 N. Old Woodward			1617	
Birmingham, M	1I 48009			

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application N .	Applicant(s)				
Advisory Action	09/901,214	AMIDON ET AL.				
	Examiner	Art Unit				
	San-ming Hui	1617				
The MAILING DATE of this communication appe	ears on the cover sheet with the c	orrespondence address				
THE REPLY FILED 27 October 2003 FAILS TO PLACE Therefore, further action by the applicant is required to av final rejection under 37 CFR 1.113 may only be either: (1) condition for allowance; (2) a timely filed Notice of Appeal Examination (RCE) in compliance with 37 CFR 1.114.	oid abandonment of this applicate) a timely filed amendment which	ation. A proper reply to a				
PERIOD FOR RE	EPLY [check either a) or b)]					
a) $\boxtimes$ The period for reply expires $\underline{3}$ months from the mailing date						
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire I ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).  Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Office timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Office timely filed, may reduce any earned patent term adjustment.	ater than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF THe date on which the petition under 37 CF of extension and the corresponding amounthe shortened statutory period for reply the later than three months after the mail	g date of the final rejection. HE FINAL REJECTION. See MPEP R 1.136(a) and the appropriate extension unt of the fee. The appropriate extension originally set in the final Office action; or				
1. A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CFF						
2. The proposed amendment(s) will not be entered be						
(a) ⊠ they raise new issues that would require further		see NOTF below):				
(b) they raise the issue of new matter (see Note be		,,,				
(c) ⊠ they are not deemed to place the application in issues for appeal; and/or	·	rially reducing or simplifying the				
(d) they present additional claims without canceli	ng a corresponding number of fi	nally rejected claims.				
NOTE: See Continuation Sheet.						
	3. Applicant's reply has overcome the following rejection(s):					
Newly proposed or amended claim(s) would canceling the non-allowable claim(s).		eparate, timely filed amendment				
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for application in condition for allowance because: See		dered but does NOT place the				
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	ause it is not directed SOLELY t	o issues which were newly				
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we						
The status of the claim(s) is (or will be) as follows:						
Claim(s) allowed:						
Claim(s) objected to:						
Claim(s) rejected:						
Claim(s) withdrawn from consideration:						
8. The drawing correction filed on is a) approved or b) disapproved by the Examiner.						
9. Note the attached Information Disclosure Statement(s)( PTO-1449) Paper No(s).						
10. Other:						

SREENI PADMANABHAN SUPERVISORY PATENT EXAMINER

50/8/11 a

## Continuation She t (PTOL-303)

Application No. 009/901,214

Continuation of 2. NOTE: The proposed amendments filed October 27, 2003 have added new limitations in attempt to clarify the herein claimed subject matters. However, the proposed limitation "of a dimension the same as the drug particle" would raise new issue of the claims. Such limitation is used to describe the drug in bulk powder form. It is not clear what "dimension" is referred to in the instant case. Is it shape or size of the drug in bulk powder forms? The claim also recite the dissolution rate of the drug in the drug particle is two-fold a what of the drug in bulk form. It is not clear what ratio of the gelatin and lecithin is needed to accomplished such characteristics. It is not clear what matrix is referred to. The proposed amendments would make the claim even more confusing than before..

Continuation of 5. does NOT place the application in condition for allowance because: Applicant's arguments filed October 27, 2003 averring the unexpected benefits of the instant invention is that only two ingredients: lecithin and gelatin, would be able to increase the solubility of the drug particles have been considered, but are not found persuasive. The claims herein recite more than the two ingredient and claim 1 does not even recite any specific ingredients. Therefore, the arguments drawn to unclaimed limitation is moot.